Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

841.21 -2.34 (-0.28%)
Streaming Delayed Price Updated: 10:28 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 44,849
Open 838.51
Bid (Size) 840.71 (80)
Ask (Size) 841.57 (40)
Prev. Close 843.55
Today's Range 835.37 - 842.38
52wk Range 510.06 - 934.62
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗
This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+0.1%
+0.1%
1 Month
+3.9%
+3.9%
3 Month
-8.4%
-8.4%
6 Month
+28.1%
+28.1%
1 Year
+31.6%
+31.6%

More News

Read More
News headline image
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
Via The Motley Fool
News headline image
Earnings Scheduled For October 30, 2025 ↗
Via Benzinga
News headline image
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
Via The Motley Fool
News headline image
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
Via Finterra
Topics ETFs Economy Initial Public Offering
News headline image
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
From argenx SE
Via GlobeNewswire
News headline image
argenx Highlights 2026 Strategic Priorities
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Leadership Transition Marking Next Evolution of Growth
From argenx SE
Via GlobeNewswire
News headline image
Beyond the Bot: 2026 Marks the Great Rebalancing as Investors Pivot from AI Hype to Tangible Growth
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology
Via PredictStreet
Topics Economy Intellectual Property
News headline image
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
From argenx SE
Via GlobeNewswire
News headline image
ARGENX SE (NASDAQ:ARGX) Combines Minervini Trend Strength with Explosive Fundamental Growth ↗
Via Chartmill
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
Via Benzinga
News headline image
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
argenx Announces Results of Extraordinary General Meeting of Shareholders
From argenx SE
Via GlobeNewswire
News headline image
Argenx SE - ADR (NASDAQ:ARGX) Fits Navellier's 'Little Book' Growth Rules ↗
Via Chartmill
News headline image
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗
Via Benzinga
News headline image
Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports ↗
Via Investor's Business Daily
News headline image
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
From argenx SE
Via GlobeNewswire
News headline image
ARGENX SE - ADR (NASDAQ:ARGX) Shows Strong Growth Traits Matching Navellier's Criteria ↗
Via Chartmill
News headline image
argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
From argenx SE
Via GlobeNewswire

Frequently Asked Questions

Is argenx SE - American Depositary Shares publicly traded?
Yes, argenx SE - American Depositary Shares is publicly traded.
What exchange does argenx SE - American Depositary Shares trade on?
argenx SE - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for argenx SE - American Depositary Shares?
The ticker symbol for argenx SE - American Depositary Shares is ARGX on the Nasdaq Stock Market
What is the current price of argenx SE - American Depositary Shares?
The current price of argenx SE - American Depositary Shares is 841.21
When was argenx SE - American Depositary Shares last traded?
The last trade of argenx SE - American Depositary Shares was at 02/18/26 10:28 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.